Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 7, 2014; 20(29): 9633-9652
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.9633
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.9633
Table 1 Boceprevir and telaprevir response guided therapy and futility rules
| End-point | Boceprevir | Telaprevir |
| RGT | Non-cirrhotic treatment naïve patients, previously relapsers or partial responders | Non-cirrhotic treatment naïve patients previously relapsers |
| HCV-RNA undetectable at weeks 8 and 24 | HCV-RNA undetectable at weeks 4 and 24 | |
| Futility rules | HCV-RNA > 100 IU/mL at week 12 | HCV-RNA > 1000 IU/mL at weeks 4 and 12 |
| HCV-RNA detectable at week 24 | HCV-RNA detectable at week 24 |
- Citation: Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol 2014; 20(29): 9633-9652
- URL: https://www.wjgnet.com/1007-9327/full/v20/i29/9633.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i29.9633